Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Hopital Saint Antoine

Research site

France 184 Rue Du Faubourg Saint Antoine, 75571 Paris, France

  • 55 trials recruiting
  • Plasma cell myeloma · Colorectal cancer metastatic · HIV infection
  • Adults and children

About Specializations

Hopital Saint Antoine in Paris, France specialises in clinical trials of conditions such as Plasma cell myeloma, Colorectal cancer metastatic, HIV infection, Acute myeloid leukaemia, and other specialisations. This site conducts important research.

Main research areas of the site

Crohn's Disease

The medical center is at the forefront of research in Crohn's Disease, focusing on innovative therapeutic approaches to manage and potentially heal this chronic inflammatory condition.

  • Transmural Healing with Guselkumab
  • Local Co-administration of Autologous ADSVF and Microfat
  • Oral TAK-279 for Endoscopic Response

These studies aim to enhance the quality of life for patients by exploring new treatment modalities that target the disease at a molecular level.

HIV and Co-infections

Our center is pioneering research in the treatment of HIV and its co-infections, with a focus on innovative therapies that aim to improve patient outcomes and manage viral loads effectively.

  • Broadly Neutralizing Antibodies in HIV-1 Infection
  • Dual Antiretroviral Therapy with Long-acting Agents
  • Management of HIV-HBV Co-infection

These trials are crucial in developing strategies that could lead to prolonged remission and better management of co-infections.

Colorectal Cancer

The center is advancing research in Colorectal Cancer, focusing on late-line treatments and personalized medicine approaches to improve survival rates and quality of life for patients.

  • Relatlimab-Nivolumab Combination Therapy
  • EO4010 Cancer Vaccine with Immune Checkpoint Blockers
  • Regorafenib-Based Personalized Treatment

These studies are designed to explore novel therapeutic combinations and optimize treatment regimens for better patient outcomes.

Multiple Myeloma

Our institution is leading research in Multiple Myeloma, focusing on innovative drug combinations and treatment strategies to enhance patient survival and quality of life.

  • Talquetamab and daratumumab Combinations
  • Isatuximab with lenalidomide and dexamethasone
  • Ixazomib, iberdomide, and dexamethasone in Relapse

These trials aim to provide new insights into effective treatment regimens and improve clinical outcomes for patients with this challenging condition.

Pancreatic Cancer

The center is at the cutting edge of research in Pancreatic Cancer, focusing on novel therapeutic approaches to improve survival rates and patient quality of life.

  • OSE2101 Plus FOLFIRI Maintenance Therapy
  • Dostarlimab with mFOLFIRINOX and Vitamin D3

These studies are crucial in exploring new treatment paradigms and enhancing the efficacy of existing therapies.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
184 Rue Du Faubourg Saint Antoine75571 ParisFrance
Open in maps ↗
Recruiting now
55 trials
Conditions studied
85

More sites in ParisFrance

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

147 clinical trials

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Metabolic dysfunction-associated steatohepatitis

Recruiting

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Glaxosmithkline Research & Development Limited

Metabolic dysfunction-associated steatohepatitis

Recruiting

Safety and Efficacy of Efimosfermin Alfa in Participants with Biopsy‑Confirmed F2‑ or F3‑Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Glaxosmithkline Research & Development Limited

Oesophageal squamous cell carcinoma

Recruiting

Study of Ifinatamab Deruxtecan and Chemotherapy for Patients with Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Daiichi Sankyo Inc.

Crohn's disease

Recruiting

Study on the Effects of Zasocitinib for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

Crohn's disease

Recruiting

One-Year Effectiveness Study of Guselkumab in Adults with Crohn’s Disease

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Guselkumab
  • Sponsor:Groupe D'etude Therapeutique Des Affections Inflammatoires Du Tube Digestif

Acute lymphocytic leukaemia

Recruiting

Study of blinatumomab and a drug combination for older adults with newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Asparaginase
  • Sponsor:Amgen Inc.

Acquired C1 inhibitor deficiency

Recruiting

Study to evaluate the efficacy and safety of deucrictibant for the prevention and treatment of angioedema attacks in adults with acquired angioedema

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Deucrictibant
  • Sponsor:Pharvaris Netherlands B.V.

Metabolic dysfunction-associated liver disease

Recruiting

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:LY3437943 sodium
  • Sponsor:Eli Lilly & Co.

Adenocarcinoma pancreas

Recruiting

Study of Gemcitabine with Paclitaxel versus Standard Chemotherapy Combination for Patients with Borderline Resectable Pancreatic Cancer Based on Gene Analysis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Fondation Franc.Cancerologie Digestive

Myelodysplastic syndrome+1

Recruiting

Study of momelotinib in patients with VEXAS syndrome and myelodysplastic syndrome who are dependent on or do not respond to steroid treatment

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Momelotinib Dihydrochloride Monohydrate
  • Sponsor:Groupe Francophone Des Myelodysplasies

Crohn's disease

Recruiting

Study on Fecal Microbiota Transplantation for Crohn's Disease Patients in Remission After Stopping Anti-TNF Therapy

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Placebo
  • Sponsor:Assistance Publique Hopitaux De Paris
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.